Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berobenatide PK Comparability Study in Adults with Overweight or Obesity
NCT07876531Phase 1Not yet recruiting
- Sponsor
- Pfizer
- Start
- Oct 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of berobenatide in obesity (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration Versus Time Curve at 85 days and Maximum Observed Concentration at 85 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
berobenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07876531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876531.